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Abstract Induction of the antioxidant enzyme heme
oxygenase-1 (HO-1) affords cellular protection and sup-
presses proliferation of vascular smooth muscle cells
(VSMCs) associated with a variety of pathological cardiovas-
cular conditions including myocardial infarction and vascular
injury. However, the underlying mechanisms are not fully
understood. Over-expression of Cav3.2 T-type Ca
2+ channels
in HEK293 cells raised basal [Ca2+]i and increased prolifera-
tion as compared with non-transfected cells. Proliferation and
[Ca2+]i levels were reduced to levels seen in non-transfected
cells either by induction of HO-1 or exposure of cells to the
HO-1 product, carbon monoxide (CO) (applied as the CO
releasing molecule, CORM-3). In the aortic VSMC line
A7r5, proliferation was also inhibited by induction of HO-1
or by exposure of cells to CO, and patch-clamp recordings
indicated that CO inhibited T-type (as well as L-type) Ca2+
currents in these cells. Finally, in human saphenous vein
smooth muscle cells, proliferation was reduced by T-type
channel inhibition or by HO-1 induction or CO exposure.
The effects of T-type channel blockade and HO-1 induction
were non-additive. Collectively, these data indicate that HO-1
regulates proliferation via CO-mediated inhibition of T-type
Ca2+ channels. This signalling pathway provides a novel
means by which proliferation of VSMCs (and other cells)
may be regulated therapeutically.
Keywords Heme oxygenase . Carbonmonoxide . Calcium
channel . Proliferation . Vascular smoothmuscle
Introduction
Vascular smooth muscle cells (VSMCs) control vascular tone
(and hence blood flow and distribution) through regulated
contraction which is highly dependent on Ca2+ influx, primar-
ily via voltage-dependent L-type Ca2+ channels [4, 21, 33, 48,
50, 54]. VSMCs are not terminally differentiated and can
undergo adaptive phenotypic changes: their ability to become
non-contractile, proliferative cells is an important factor in
both developmental vasculogenesis and vascular repair [35,
36, 52]. However, this switch to a proliferative state is also
important in pathological situations such as atherosclerosis,
restenosis, neointimal hyperplasia and hypertension [19, 36].
Given the impact of such cardiovascular diseases on global
health, a greater understanding of the mechanisms underlying
this phenotypic change in VSMCs has tremendous potential to
reveal novel therapeutic strategies.
Although T-type Ca2+ channels are expressed in VSMCs,
their role in vasoconstriction is unclear (see [10]). However, in
proliferating VSMCs, whilst L-type Ca2+ channel expression
decreases, T-type Ca2+ channel expression has long been
known to increase [26, 42], and Ca2+ influx via T-type Ca2+
channels appears to be required for proliferation in vitro and
neointima formation following vascular injury [26, 29, 43,
45]. The implication of a role for T-type Ca2+ channels has
often been based on the use of mibefradil [29, 45], which is
now known to exert effects on targets other than T-type Ca2+
channels (e.g. [15]). However, more recent molecular
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approaches have confirmed this class of channel as being of
primary importance in vascular proliferation [43, 47].
Heme oxygenase (HO) enzymes catalyse the degradation
of heme to biliverdin, Fe2+ and carbon monoxide (CO).
Whilst HO-2 is constitutively active and widely distributed,
HO-1 is induced by a variety of cellular stresses [23, 44] and
regarded as protective, since heme itself is pro-oxidant, and
biliverdin is rapidly converted to the powerful antioxidant,
bilirubin. HO-1 induction affords protection in a variety of
pathological cardiovascular conditions including myocardial
infarction, hypertension, atherosclerosis and vascular injury,
many of which involve VSMC proliferation [8, 44]. Indeed,
HO-1 is established as being anti-proliferative, and CO may
account for many of the effects of HO-1 in VSMCs [12, 13,
34]: inhalation of CO can inhibit the proliferation of VSMCs
in intimal hyperplasia following vessel grafting [34, 41] and
CO inhalation, as well as CO-releasing molecules (CORMs),
are being developed for future cardiovascular therapy [14]
despite the detailed mechanisms underlying its anti-
proliferative effect remaining unknown. In recent years, we
and others have suggested that specific ion channels are
targets of regulation by CO and that their modulation may
account for some of the important actions of CO [11, 22, 46,
53].
We have most recently demonstrated that recombinant and
native neuronal T-type Ca2+ channels are inhibited by CO [5].
In the present study, we have investigated the potential role of
T-type Ca2+ channel regulation by CO on cellular proliferation.
Methods
Cell culture
A7r5 cells A7r5 cells (a smooth muscle cell line derived from
rat thoracic aorta [24]) were obtained from the European
Collection of Cell Cultures (ECACC, Public Health
England, Porton Down, UK). They were grown in A7r5
complete media, consisting of Dulbecco's Modified Eagle
Medium (DMEM) containing 10 % foetal bovine serum
(FBS) (Biosera, Ringmer, UK) and 1 % glutamax (Gibco,
Paisley, UK). Cells were kept in a humidified incubator at
37 °C (95 % air: 5 % CO2) and passaged weekly.
Human saph enou s v e i n smoo t h mus c l e c e l l s
(HSVSMCs) Smooth muscle cells were isolated from the sa-
phenous vein (SV) of anonymous patients undergoing coro-
nary bypass graft surgery at Leeds General Infirmary follow-
ing ethical approval and informed patient consent. Segments
of SV, around 1 cm in length, were denuded of endothelium
and adventitia and were cut open longitudinally, lumen facing
upwards. The segment was then divided into two pieces. Two
milliliters of complete medium (DMEM containing 10% (v/v)
FBS (Biosera, Ringmer, UK), 1 % (v/v) L-glutamine and 1 %
(v/v) penicillin/streptomycin (Gibco, Paisley, UK; unless oth-
erwise stated)) were transferred into a clean petri dish and a
segment of vein placed in the media. This was then cut with a
razorblade into fragments around 0.5 mm2 in size. This tissue
and media mixture was then transferred to a 25-cm2 tissue
culture flask and maintained in a humidified atmosphere
(37 °C; 95 % air: 5 % CO2). Cells migrated out from these
tissue fragments within 7–10 days, and when 80–90 % con-
fluent, the cells were plated for experimentation. HSVSMCs
were used at passages between P1 and P6.
HEK293 cells Wild type (WT; untransfected) HEK293 cells
were cultured in minimum essential medium containing
Earle’s salts and L-glutamine and supplemented with 10 %
(v/v) foetal bovine serum (Biosera, Ringmer, UK), 1 % (v/v)
non-essential amino acids, 1 % (v/v) antibiotic/antimycotic
and 0.1 % (v/v) gentamicin. HEK293 cells stably expressing
Cav3.2 T-type Ca
2+ channels (a kind gift from Prof. E. Perez-
Reyes; University of Virginia, VA, USA) were cultured inWT
HEK293 media, additionally supplemented with 1 mg/ml
G-418 to maintain selection pressure (all reagents from
Gibco, Paisley, UK; unless otherwise stated). HEK293/
Cav3.2 cells were used at passages between P1 and P8, and
WT HEK293 cells were used at passages between P1 and
P12; both cell types were kept in a humidified incubator at
37 °C (95 % air: 5 % CO2) and passaged weekly.
Proliferation assay
Cells were plated in 24-well plates in complete media at 1×
104 cells per well. HSVSMCs were allowed to adhere over-
night and subjected to serum free media (SFM) for 2.5 days.
A7r5 and HEK293 cells were allowed to adhere for 6 h and
then subjected to SFM overnight. On day 0 of the assay, SFM
was removed and 1 ml of the relevant complete media was
added to each well, in addition to the required drug or com-
pound being investigated. To count cells, media was removed,
cells were washedwith 1ml of Dulbecco’s phosphate buffered
saline (PBS) and 200 μl of 0.05 % trypsin-EDTA (Gibco,
Paisley, UK) was added (pre-warmed to 37 °C). Post-
incubation, 800 μl of complete media was added and the cell
suspension centrifuged (600g for 6 min). Following removal
of 950μl of media, 50μl of supernatant remained with the cell
pellet, which was then re-suspended with 50 μl of 0.4 %
trypan blue (Thermo Scientific, Rockford, USA) to exclude
unviable cells. Media was retained from one well of each
treatment, processed in the same manner as the cell samples,
and any cells present were counted as an additional quantifi-
cation of non-viable cells. Day 0 counts and media counts
were performed using a hemocytometer. All other counts were
performed using a TC10 automated cell counter (Bio-Rad,
Hemel Hempstead, UK).
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Western blotting
HSVSMCs, WT HEK293 and HEK293/Cav3.2 cells were
grown to 80 % confluence in 6-well plates. The wells were
replenished with 0.4 % serum-containing media plus the
required concentration of cobalt protoporphyrin IX
(CoPPIX). Post-treatment, the cells were washed with PBS
and lysed via incubation for 30 min with 200 μl mammalian
protein extraction reagent (M-PERTM; Thermo Scientific,
Rockford, USA) containing complete mini protease inhibitors
(Roche Diagnostics Ltd., Lewes, UK). Cell lysates were re-
trieved and protein levels determined using a BCA protein
assay kit according to manufacturers’ instructions (Thermo
Scientific, Rockford, USA). Protein (10–20μg) containing 2×
sample buffer (250 mM Tris/HCl, pH 6.8, 4 % (w/v) SDS,
20 % (w/v) glycerol, 1 % bromophenol blue and 10 % β-
mercaptoethanol) was loaded onto 12.5 %, 0.75-mm-thick
polyacrylamide-sodium dodecyl sulphate gels and separated
for ~1 h at 35 mA before being transferred onto 0.2 μm
polyvinyl difluoride membranes at 30 V overnight.
Membranes were blocked using 5 % (w/v) non-fat dried milk
powder in tris buffered saline (TBS)-tween (0.05 %) for 1 h,
then incubated with rabbit anti-HO-1 antibody raised against
amino acids 184–288 of human HO-1 (SC-10789; Santa
Cruz, Dallas, USA) at 1:200 for 3 h at room temperature
(21–24 °C). Mouse anti-β-actin raised against the N-
terminal of β-actin (Sigma, Gillingham, UK) was used as a
loading control at 1:4,000. The membranes were then washed
in TBS-tween (0.05 %) and incubated with the corresponding
anti-rabbit or anti-mouse peroxidase-conjugated secondary
antibody (GE Healthcare, Amersham, UK) at 1:2,000 for 1 h
at room temperature. Protein bands were detected using the
enhanced chemi-luminescent method (GE Healthcare,
Amersham, UK) on hyperfilm. Densitometric analysis was
performed using Image J (NIH UK).
Electrophysiology
Ca2+ currents were recorded from A7r5 cells using the whole-
cell configuration of the patch-clamp technique at room tem-
perature (21–24 °C) as previously described [5] using an
Axopatch 200A amplifier/Digidata 1300 interface controlled
by Clampex 9.0 software (Molecular Devices, Sunnyvale,
CA, USA). Offline analysis was performed using Clampfit
9.0. Pipettes (4–6 MΩ) were filled with (in mM) the
following: CsCl 120, MgCl2 2, EGTA 10, TEA-Cl 20,
HEPES 10, Na-ATP 2 and pH 7.2 (adjusted with CsOH). To
optimise recording of T-type Ca2+ currents, cells were per-
fused with (in mM) the following: NaCl 95, CsCl 5,
MgCl2 0.6, CaCl2 15, TEA-Cl 20, HEPES 5, D-glucose 10
and pH 7.4 (adjusted with NaOH). Cells were voltage-
clamped at −80 mV and either repeatedly depolarized to
−20 mV (200 ms, 0.1 Hz) or to a series of test potentials
ranging from −100 to +60 mV. To record L-type Ca2+ currents,
extracellular Ca2+ was replaced with 20 mM Ba2+ (pH 7.4,
adjusted with NaOH) and a holding potential of −50 mV was
employed in order to inactivate T-type Ca2+ channels. Cells
were repeatedly depolarized to +10 mV (200 ms, 0.1 Hz). All
currents were low-pass filtered at 2 kHz and digitised at
10 kHz.
Real-time polymerase chain reaction (RT-PCR)
To determine mRNA expression levels of Cav3.2 and Cav3.1
channels, T75 flasks (70–80% confluency) were washed with
PBS and cells dissociated using 0.5 ml 0.05 % trypsin-EDTA
for 3 min (37 °C; 95 % air: 5 % CO2). Enzyme activity was
halted by adding 0.5-ml ice-cold PBS; the cell suspension was
then centrifuged (600g for 6 min). RNA was generated from
whole cell lysates using the Aurum total RNA mini kit (Bio-
Rad, Hemel Hempstead, UK) following manufacturer’s in-
structions. A cDNA template was generated from RNA sam-
ples using the iScript cDNA synthesis kit (Bio-Rad, Hemel
Hempstead, UK) following manufacturer’s instructions (reac-
tion profile was 5 min at 25 °C, 30 min at 42 °C, 5 min at
85 °C, 5 min at 4 °C). Rat or human Taqman probes (Applied
Biosystems (ABI), UK) for Cav3.1 (CACNA1G), Cav3.2
(CACNA1H) and the endogenous housekeeper hypoxanthine
phosphoribosyltransferase (HPRT1) were employed for A7r5
cells and HSVSMC, respectively. In all cases, 2 μl of sample
cDNA and 18 μl of RT-PCR reaction mix (10 μl Taqman
universal PCR master mix, 0.5 μl Taqman probes (both from
ABI) and 7.5 μl RNase/DNase-free water (Gibco, Cambridge,
UK)) were added to the required wells of a 96-well PCR plate
(Applied Biosystems, Cambridge, UK). RT-PCR was carried
out using an ABI 7500 real-time PCR system (reaction profile
was 2 min at 50 °C, 10 min at 95 °C, 15 s at 95 °C for
60 cycles, 1 min at 60 °C). Data were analysed using the
7500 software (ABI) and relative gene expression calculated
using the 2−ΔΔCT method with HPRT1 as the endogenous
control.
Ca2+ microfluorimetry
WT HEK293 or HEK293/Cav3.2 cells were plated at the
required cell density on circular glass coverslips (10 mm,
thickness 0) and allowed to adhere overnight. Cells were
washed and incubated with 4 μM Fura 2-AM (Invitrogen,
Cambridge, UK) diluted in HEPES-buffered saline for 40 min
at room temperature (21–24 °C). Composition of HEPES-
buffered saline was (in mM): NaCl 135, KCl 5, MgSO4 1.2,
CaCl2 2.5, HEPES 5, glucose 10, osmolarity adjusted to
300 mOsm with sucrose, and pH adjusted to 7.4. The Fura
2-containing saline was removed after 40 min and replaced
with HEPES-buffered saline for 15 min to allow de-
esterification. Coverslip fragments were loaded into a
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perfusion chamber on an inverted epifluorescence micro-
scope, and the cells were superfused via gravity at 2–3 ml/
min. [Ca2+]i was indicated by fluorescence emissionmeasured
at 510 nm as a result of alternating excitation at 340 and
380 nm using a Cairn Research ME-SE Photometry system
(Cairn Research, Cambridge, UK). Baseline readings were
obtained on exposure to HEPES-buffered saline, and Ca2+
homeostasis was monitored in response to the addition of a
drug, or in response to Ca2+-free HEPES-buffered saline
(composition as above, but with CaCl2 replaced by 1 mM
EGTA).
Statistical comparisons were made using, as appropriate,
paired or unpaired student’s t tests, one-way ANOVA with a
multiple comparison test or repeated measures one-way
ANOVAwith a multiple comparison test.
Results
CO regulation of T-type Ca2+ channels regulates proliferation
in A7r5 cells
The known role of T-type Ca2+ channels in proliferation (see
“Introduction”), together with our recent study indicating that
CO can directly modulate T-type Ca2+ channels [5], indicates
that HO-1-derived CO can limit proliferation via inhibition of
T-type Ca2+ channels. To investigate this, we employed A7r5
cells, which are derived from rat aortic smooth muscle [24]
and express T-type Ca2+ channels as well as L-type Ca2+
channels [6, 30, 39]. Mibefradil caused a concentration-
dependent decrease in proliferation, as determined after 3 days,
without loss of cell viability (Fig. 1a). By contrast, nifedipine
did not significantly affect proliferation over the same time
period at concentrations up to 4 μM (Fig. 1b). A previous
electrophysiological study indicated that at 1 μM mibefradil
was selective for T-type over L-type Ca2+ channels in A7r5
cells [6], but did not explore higher concentrations. Therefore,
to probe the role of T-type Ca2+ channels in proliferation
further, we also found that an alternative and more selective
T-type Ca2+ channel blocker, NNC-55-0396 [20], significant-
ly reduced proliferation at 3 μM (Fig. 1c), but was toxic to
cells at higher concentrations (not shown). Finally, we inves-
tigated the effects of Ni2+, a known T-type Ca2+ channel
inhibitor. Importantly, these studies were performed in the
presence of 2 μM nifedipine in order to prevent any potential
influence of L-type Ca2+ channel blockade by Ni2+ on prolif-
erative responses. Ni2+ caused a concentration-dependent in-
hibition of proliferation, as shown in Fig. 1d. The data pre-
sented in Fig. 1 strongly suggest that Ca2+ influx via T-type,
but not L-type Ca2+ channels, contributes to the proliferation
of A7r5 cells.
Exposure of A7r5 cells to CoPPIX caused a concentration-
dependent increase in the expression of HO-1, as detected by
Western blotting (Fig. 2a). This procedure for induction of
HO-1 caused a significant reduction of proliferation in A7r5
cells (Fig. 2b). Furthermore, proliferation of A7r5 cells was
strikingly reduced by exposure of cells to CORM-3 (Fig. 2c).
Collectively, the data presented in Figs. 1 and 2 suggest that
proliferation in A7r5 cells is dependent on T-type Ca2+ chan-
nel activity and can be inhibited by induction of HO-1 or
exposure to CO. To investigate whether CO acted via inhibi-
tion of native T-type Ca2+ channels in these cells, we exam-
ined their activity using whole-cell patch-clamp recordings. T-
type Ca2+ channel currents, recorded using a holding potential
of −80 mV and Ca2+ as the charge carrier, were inhibited by
exposure of cells to CORM-2 but not to iCORM (Fig. 3a, c).
Where tested (e.g. Fig. 3a), these currents were also inhibited
by 3 μM NNC 55-0396 (93.2±5.9 % inhibition, n=5). To
study L-type Ca2+ currents, we used a holding potential of
−50 mV (in order to inactivate T-type Ca2+ channels) and
replaced Ca2+ with Ba2+ to promote influx via L-type rather
than T-type Ca2+ channels. Under these conditions, currents
displaying little or no inactivation were also inhibited by
CORM-2 but not iCORM (Fig. 3b, c) and, where tested (e.g.
Fig. 3b), were inhibited by 2 μM nifedipine (88.5±6.2 %
inhibition, n=5). Thus, CO can inhibit both T-type and L-type
Ca2+ channels natively expressed in A7r5 cells.
HO-1 and CO inhibit proliferation in HSVSMCs
To examine whether the HO-1/CO pathway was able to mod-
ify proliferation in human VSMCs, we studied cells cultured
from human saphenous vein. Figure 4a shows that HO-1
could be induced in these cells in a concentration-dependent
manner and that induction was clearly detectable at 2 and
4 days (the duration of associated proliferation studies).
Induction of HO-1 also led to a concentration-dependent
inhibition of proliferation over this same time period, without
loss of cell viability (Fig. 4b). To investigate whether the
reduced proliferation observed following HO-1 induction
was attributable to the production of CO, we exposed cells
to CORM-3 and found that this agent caused a concentration-
dependent inhibition of proliferation, again without any loss
of cell viability (Fig. 4c).
Figure 5a shows a proliferation time-course experiment
from HSVSMCs, and again demonstrates the inhibitory effect
of HO-1 induction, using 3 μM CoPPIX. A qualitatively and
quantitatively similar effect was found when cells were ex-
posed to the known T-type Ca2+ channel blocker, mibefradil
(3 μM; Fig. 5b), which was without effect on cell viability
(data not shown). Finally, proliferation was again reduced by a
similar amount in cells in which HO-1 had been induced, and
during an additional exposure to mibefradil (Fig. 5c), indicat-
ing that HO-1 and mibefradil are non-additive, likely because
they act via the same target, the T-type Ca2+ channel.
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Figure 6 shows the expression levels, relative to the endog-
enous housekeeper HPRT1, of mRNA for the T-type Ca2+
channel isoforms, Cav3.1 and Cav3.2, as determined by RT-
PCR. In both the A7r5 cells and HSVSMCs, the Cav3.1
isoform is expressed at significantly higher levels than the
Cav3.2 isoform, but both isoforms were detected.
CO inhibits augmented proliferation in Cav3.2-expressing
HEK293 cells
In order to better understand the cellular mechanisms under-
lying CO modulation of T-type Ca2+ channels and how this
impacts on proliferation, we employed a recombinant expres-
sion system. Preliminary studies in HEK293 cells stably ex-
pressing Cav3.1 indicated that these cells readily formed
clumps and became detached in culture, making assessment
of their effects on proliferation difficult. We therefore focussed
on cells over-expressing Cav3.2, which are also expressed in
VSMCs (see [49] as well as Fig. 6), and are equally potently
modulated by CO [5]. In agreement with a previous report
[17], we found that over-expression of Cav3.2 in HEK293
cells increased their proliferation when compared with WT
cells over a 3-day period (Fig. 7a, b). Exposure of WTcells to
the CO-releasing molecule CORM-3 (30 μM) or the inactive,
control compound iCORM (30 μM) was without significant
effect on proliferation (Fig. 7a). By contrast, exposure of
Cav3.2-expressing cells to 30 μM CORM-3 (but not
iCORM) significantly reduced proliferation (Fig. 7b).
Proliferation monitored after 3 days also revealed that
mibefradil (3 μM) was without significant effect in WT cells
(Fig. 7c), but reduced proliferation in Cav3.2-expressing cells
to levels observed in WT cells, and CORM-3 was without
further effect in the presence of mibefradil (Fig. 7d).
Cav3.2 over-expression increases basal [Ca
2+]i
Tonic Ca2+ entry via the window current generated in cells
expressing T-type Ca2+ channels is believed to regulate cell
proliferation (see “Introduction”). We employed fluorimetric
recordings from Fura-2 loaded HEK293 cells to both monitor
Ca2+ levels and determine how they were influenced by T-
type Ca2+ channel expression. Basal [Ca2+]i in HEK293
cells expressing Cav3.2 was significantly higher than
levels observed in WT cells, and removal of extracellu-
lar Ca2+ (replaced with 1 mM EGTA) caused a fall of
[Ca2+]i which was far larger than that seen in WT cells
(although the same manoeuvre also caused a significant
decrease of [Ca2+]i in these cells; Fig. 8a), in agreement
with an earlier report [9]. To determine whether the
elevated [Ca2+]i was attributable to Ca
2+ influx via the
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Fig. 1 T-type Ca2+ channel inhibitors suppress proliferation of
A7r5 cells. a–d Bar graphs showing the proliferative response
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ified drugs. Proliferation (plotted as bar graphs, corresponding to
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T-type Ca2+ channel window current, we investigated the
effects of the T-type Ca2+ channel blockers Ni2+ (30 μM;
Fig. 8b), mibefradil (3 μM; Fig. 8c) and NNC55-0396
(3 μM; Fig. 8d). All blockers caused significant reductions
in [Ca2+]i, and in the case of Ni
2+, this effect was at least partly
reversible. None of the inhibitors tested significantly altered
[Ca2+]i in WT cells (Fig. 8b–d).
HO-1 and CO regulate [Ca2+]i in Cav3.2-expressing cells
We next investigated the effects of HO-1 induction on [Ca2+]i
in HEK293 cells. As illustrated in Fig. 9a, HO-1 induction
with 10 μM cobalt protoporphyrin IX (CoPPIX) for 48 h
caused a significant reduction in basal [Ca2+]i in cells express-
ing Cav3.2, although removal of extracellular Ca
2+ reduced
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ted as bars, corresponding to the left-hand y-axis) was monitored on day 0
(solid bar) and on day 3 (open bars) in the absence or presence of
CORM-3. The open circles show the corresponding unviable cell count
(plotted against corresponding right-hand y-axis). Statistical significance
**p<0.01, ****p<0.0001 vs day 3 control (no drug). Data analysed via
one-way ANOVA (a) or ratio repeated measures one-way ANOVA (b
and c) followed by Dunnett’s multiple comparison test
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[Ca2+]i further. By contrast, HO-1 induction with 3 μM
CoPPIX in WT HEK293 cells was without significant effect
(Fig. 9a). This slightly lower concentration of CoPPIX was
selected for WT HEK293 cells, since it was found to be the
optimal concentration for HO-1 induction, as determined by
Western blotting, whereas in Cav3.2-expressing cells, max-
imal induction was achieved with 10 μM CoPPIX
(Fig. 9b). To determine whether CO mediated the effects
of HO-1 induction on resting [Ca2+]i, we applied CORM-
3 (3 μM), which caused a striking and largely irreversible
reduction of [Ca2+]i in Cav3.2-expressing HEK293 cells,
but not in WT cells (Fig. 9c). By contrast, iCORM was
without significant effect in either cell type (Fig. 9c).
Collectively, these fluorimetric studies indicate that over-
expression of Cav3.2 generates a detectable tonic Ca
2+
influx in HEK293 cells which can be suppressed either
by CO or following induction of HO-1.
Discussion
Although Ca2+ influx via L-type Ca2+ channels is important
for VSMC contraction, a reduction in their expression is
associated with the proliferative phenotypic change [16, 19],
as observed in pathological models involving VSMC prolif-
eration [40]. However, Ca2+ influx is still needed for the
progression of proliferation since it regulates the activity of
numerous transcription factors, e.g. NFAT (nuclear factor of
activated T-cells; [2]). Some studies suggest TRP (transient
receptor potential) channels, particularly TRPC channels, con-
tribute to Ca2+ influx during VSMC proliferation [19, 27].
Further evidence indicates STIM1/Orai–mediated Ca2+ entry
is also involved in VSMC proliferation, migration and neoin-
tima formation in vivo [3, 56]. However, there is also com-
pelling evidence for the involvement of voltage-gated T-type
Ca2+ channels in VSMC proliferation. Indeed, in proliferating
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VSMCs, as L-type Ca2+ channel expression decreases, there is
a concomitant increase in T-type Ca2+ channel expression [26,
42]. Evidence suggests Ca2+ influx via T-type Ca2+ channels
is required for VSMC proliferation in vitro and in neointima
formation observed following vascular injury [26, 29, 43, 45].
Although the implication of a role for T-type Ca2+ channels
has often (but not always) been based on the use of mibefradil
(which was originally proposed as a selective T-type Ca2+
channel blocker but has since been shown to exert other
effects, such as inhibition of store-operated Ca2+ entry [15]),
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mibefradil clearly blocks T-type Ca2+ channels, inhibits pro-
liferation associated with vascular injury-mediated neointima
formation and NFAT-mediated transcriptional activity [29,
45]. Furthermore, in the pulmonary vasculature, evidence for
T-type Ca2+ channels regulating proliferation comes also from
siRNA-targeted T-type (Cav3.1) Ca
2+ channel knock-down
[43]. Most convincingly, murine knockout models have re-
cently shown beyond doubt that Cav3.1 is required for VSMC
proliferation following systemic vascular injury [47].
In VSMCs expressing native T-type Ca2+ channels (A7r5
cells and HSVSMCs), data presented are also consistent with
these channels exerting an important influence on prolifera-
tion. Consistent with previous work [49], we detected
expression of both Cav3.1 and Cav3.2 in A7r5 cells, and also
detected mRNA for both channel types in HSVSMCs (Fig. 6),
and mibefradil reduced proliferation in both cell types (Figs. 1
and 5). In A7r5 cells, despite the presence of nifedipine-
sensitive L-type Ca2+ channels (Fig. 3), nifedipine was without
effect on proliferation (Fig. 1), which discounts the possibility
that mibefradil (or indeed NNC 55-0396) reduced prolifera-
tion via a non-selective blockade of L-type Ca2+ channels.
Ni2+ (studied in the presence of nifedipine) was effective at
reducing proliferation only at higher (>100 μM) concentra-
tions. This suggests that influx of Ca2+ into A7r5 cells via
T-type Ca2+ channels predominantly involves Cav3.1 rath-
er than Cav3.2 channels, since Cav0.3.2 channels would
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be expected to be already fully inhibited at these higher
Ni2+ concentrations [28].
The major finding of the present study is that HO-1 induc-
tion leads to reduced proliferation in VSMCs (both A7r5 cells,
Fig. 1, and HSVSMCs, Figs. 4 and 5) and that this occurs via
CO formation which in turn inhibits T-type Ca2+ channels.
Thus, reduced proliferation arising from HO-1 induction
could be mimicked by application of the CO-donor CORM-
3 in both cell types (Figs. 2 and 4), and in A7r5 cells, we were
able to demonstrate directly that T-type Ca2+ channels were
inhibited by CORM-2 (Fig. 3). It should be noted that we
could not use CORM-2 for proliferation studies, since cells
did not tolerate long-term exposure to its solvent, DMSO (data
not shown). CO also inhibited L-type Ca2+ channels (as we
have previously shown in cardiac myocytes [46]), but this
appears to be without influence on proliferation, since prolif-
eration was insensitive to nifedipine (Fig. 1b). The reasonwhy
L-type Ca2+ channels do not influence proliferation in these
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cells is unknown, but may be due to a lack of tonic activity at
the cell’s resting membrane potential. In HSVSMCs, the lack
of additive effects of HO-1 induction and mibefradil exposure
on proliferation further support the idea that T-type Ca2+
channel modulation by CO accounts for the inhibition of
proliferation by HO-1. These data, combined with our recent
electrophysiological study directly demonstrating inhibition
of all 3 isoforms of T-type Ca2+ channels by CO [5], and also
the observation that HO-1 induction or exposure to CO re-
duces basal [Ca2+]i in Cav3.2-expressing cells and reduces
proliferation, collectively argue strongly that VSMC prolifer-
ation can be regulated via T-type Ca2+ channel modulation by
CO derived from HO-1.
T-type Ca2+ channels are also clearly associated with pro-
liferation in other cell types, including certain cancers [37],
where they represent viable therapeutic targets (e.g. [18]). The
present study also demonstrates, in agreement with an earlier
report [17], that over-expression of T-type Ca2+ channels (in
this case, Cav3.2; Fig. 7) in HEK293 cells promotes prolifer-
ation. This increase is attributable to Ca2+ influx via these
channels, since inhibition with mibefradil reduced prolifera-
tion rates to levels observed in WTcells (i.e. not expressing T-
type Ca2+ channels). Furthermore, Cav3.2-mediated increases
in proliferation were associated with increased basal [Ca2+]i
(Fig. 8), suggesting that tonic Ca2+ influx via Cav3.2 provided
a sustained elevation of [Ca2+]i which promoted proliferation.
This presumably occurs via the well-described T-type Ca2+
channel ‘window current’ [38] which arises from a small
proportion of the total T-type Ca2+ channel population that
retains tonic activity (i.e. partially activated and not fully
inactivated) at or around the cell’s resting membrane potential.
The presence of a window current generated by expressed
Cav3.2 channels would also require that native currents set the
resting membrane potential appropriately. The nature of such
currents has not to date been explored in depth.
Numerous studies have indicated that HO-1 induction af-
fords protection in a variety of pathological systemic cardio-
vascular conditions, many of which involve VSMC prolifer-
ation [8, 44]. Indeed, HO-1 is established as being anti-
proliferative, and its induction is observed in these prolifera-
tive vascular diseases. For example, proliferation associated
with hypertension is suppressed by HO-1 induction [7], and
many studies have indicated that HO-1 protects against in-
flammation and oxidative stress associated with atherosclero-
sis [1]. Furthermore, whilst bilirubin is a powerful antioxidant
in its own right, evidence points towards CO as accounting for
many of the effects of HO-1 in VSMCs [12, 13, 34]. For
example, inhalation of CO inhibits VSMC proliferation in
intimal hyperplasia following vessel grafting [34, 41] and
CO inhalation, as well as CO-releasing molecules (CORMs),
is being developed for future cardiovascular therapy [14, 32].
HO-1 is also influential in the pulmonary vasculature: hypoxic
induction of pulmonary hypertension (and hence right ven-
tricular dilation) was far worse in HO-1−/− mice [55], and
targeted pulmonary over-expression of HO-1 prevents inflam-
mation and pulmonary vessel wall hypertrophy (including
VSMC proliferation) in response to hypoxia [31]. Clearly,
HO-1 is beneficial in providing protection against pulmonary
remodelling, and speculation that COmediates these effects of
HO-1 has been made in earlier publications [25]. More recent
studies have provided direct evidence that CO inhalation in
HO-1−/− mice prevented hypoxic pulmonary remodelling and
inhibited hypoxic VSMC proliferation in vitro, whereas bili-
verdin was ineffective [51].
Despite these numerous accounts of the beneficial effects
of CO derived from HO-1 induction in both systemic and
pulmonary vascular diseases, no mechanism has been pro-
posed to account for such effects to date. The data presented
here provide compelling evidence that CO may provide pro-
tection against proliferative vascular diseases at least in part
via inhibition of T-type Ca2+ channels. Since CO can regulate
all three isoforms of T-type Ca2+ channels (Cav3.1, 3.2 and 3.3
[5]), this regulation can occur regardless of which isoform is
expressed. The present data therefore provide mechanistic
insight into the beneficial cardiovascular effects of HO-1 and
CO and also point to a novel signalling pathway which can be
targeted in future treatment strategies for vascular diseases.
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Fig. 9 HO-1 and CO modulate basal [Ca2+]i in Cav3.2-expressing
HEK293 cells. a Upper traces show examples of basal [Ca2+]i recorded
in Cav3.2-expressing cells (left traces and bar graph) andWTcells (right
traces and bar graph). Cells received either no pre-treatment, or were
exposed to 10 μM CoPPIX (Cav3.2) or 3 μM CoPPIX (WT) for 48 h to
induce HO-1 expression (+CoPPIX). For the periods indicated by the
horizontal bars, extracellular Ca2+ was replaced with 1 mM EGTA.
Below; Bar graphs illustrating the mean (± s.e.m.) basal [Ca2+]i levels
recorded in Cav3.2-expressing cells (left bar graph, n=16) and WT cells
(right bar graph, n=12) before (con.), during (Ca2+ free) and after (con.)
removal of extracellular Ca2+. Open bars; control cells. Shaded bars;
exposed to 10 μM CoPPIX (Cav3.2) or 3 μM CoPPIX (WT) for 48 h to
induce HO-1 expression (+CoPPIX). Statistical significance **P<0.01,
***P<0.001 as compared with appropriate controls. b Western
blots showing the concentration-dependent induction of HO-1
expression by CoPPIX. Corresponding β-actin blots are shown
below, and data were obtained in Cav3.2-expressing (left) and WT
(right) HEK293 cells. c Upper traces show examples of basal
[Ca2+]i recorded in Cav3.2-expressing and WT HEK293 cells, as
indicated, and the effects of CORM-3 (3 μM; left traces) and
iCORM (3 μM; right traces) applied for the periods indicated by
the horizontal bars. Below; bar graph illustrating the mean
(± s.e.m.) basal [Ca2+]i levels recorded in Cav **P<0.01
P<0.001"?> as compared with appropriate controls. Data analysed
via paired or unpaired t test as appropriate
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